EP Patent

EP2125819B1 — Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases

Assigned to Bristol Myers Squibb Co · Expires 2014-10-22 · 12y expired

What this patent protects

Patent listed against Wayrilz.

Drugs covered by this patent

Patent Metadata

Patent number
EP2125819B1
Jurisdiction
EP
Classification
—
Expires
2014-10-22
Drug substance claim
No
Drug product claim
No
Assignee
Bristol Myers Squibb Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.